Laviolle Bruno, Locher Clara, Allain Jean-Sébastien, Le Cornu Quentin, Charpentier Pierre, Lefebvre Marie, Le Pape Clémence, Leven Cyril, Palpacuer Clément, Pontoizeau Clémence, Bellissant Eric, Naudet Florian
CHU Rennes, Inserm, Centre d'Investigation Clinique de Rennes (CIC1414), Service de Pharmacologie Clinique, Institut de Recherche en Santé, Environnement et Travail (Irset), UMR S 1085, EHESP, Univ Rennes, Rennes, France.
Inserm, Centre d'Investigation Clinique de Rennes (CIC1414), Service de Pharmacologie Clinique, CHU Rennes, Rennes, France.
Clin Pharmacol Ther. 2025 Mar;117(3):818-825. doi: 10.1002/cpt.3535. Epub 2025 Jan 5.
Studies with negative results are less likely to be published than others, potentially leading to publication bias. Introduced in 2000, trial registration could have participated in decreasing the proportion of unpublished studies. We assessed the proportion of negative randomized controlled trials (RCT) over the last 20 years. We searched Medline for RCT published in 2000, 2005, 2010, 2015, and 2020 in the British Medical Journal, the Journal of the American Medical Association, the Lancet, and the New England Journal of Medicine. The primary endpoint was the proportion of negative (final comparison on the primary study-endpoint without statistical significance or favoring the control arm) studies published in 2000 and 2020. Factors independently associated with the publication of negative studies were identified using multivariable analysis. A total of 1,542 studies were included. The proportion of negative RCT significantly increased between 2000 and 2020 (from 27.6% to 37.4%; P = 0.01), however, the trend over time was not significant (P = 0.203). In multivariable analysis, the following factors were associated with a higher proportion of published negative studies: superiority (P < 0.001), two-group trials (P < 0.001), number of patients ≥510 (P < 0.001), cardiology trials (P = 0.003), emergency/critical care trials (P < 0.001), obstetrics trials (P = 0.032), surgery trials (P = 0.006), pneumology trials (P = 0.029). Exclusive industry funding was associated with a lower proportion of published negative studies (P < 0.001). The proportion of published negative studies in 2020 was higher only when compared to 2000. During the two decades, no trend was noticeable. There is no clear relationship between trial registration and the publication of negative results over time.
与其他研究相比,结果为阴性的研究发表的可能性较小,这可能导致发表偏倚。试验注册于2000年开始实施,本可有助于减少未发表研究的比例。我们评估了过去20年中阴性随机对照试验(RCT)的比例。我们在《英国医学杂志》《美国医学会杂志》《柳叶刀》和《新英格兰医学杂志》上检索了2000年、2005年、2010年、2015年和2020年发表的RCT。主要终点是2000年和2020年发表的阴性(主要研究终点的最终比较无统计学意义或支持对照组)研究的比例。使用多变量分析确定与阴性研究发表独立相关的因素。共纳入1542项研究。2000年至2020年间,阴性RCT的比例显著增加(从27.6%增至37.4%;P = 0.01),然而,随时间的趋势并不显著(P = 0.203)。在多变量分析中,以下因素与发表的阴性研究比例较高相关:优效性(P < 0.001)、两组试验(P < 0.001)、患者数量≥510(P < 0.001)、心脏病学试验(P = 0.003)、急诊/重症监护试验(P < 0.001)、产科试验(P = 0.032)、外科试验(P = 0.006)、肺病学试验(P = 0.029)。仅由行业独家资助与发表的阴性研究比例较低相关(P < 0.001)。仅与2000年相比,2020年发表的阴性研究比例更高。在这二十年中,没有明显的趋势。随着时间的推移,试验注册与阴性结果的发表之间没有明确的关系。